Macrophage CAR (MOTO-CAR) in imunotherapy

A macrophage, immune cell technology, applied in blood/immune system cells, animal cells, immunoglobulins, etc., can solve the problem that the exact source and expression are not fully understood.

Pending Publication Date: 2018-06-08
迅雷生物科技有限公司
View PDF7 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Whether these DNA sequences are transcribed is unknown and most likely pseudogenes,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Macrophage CAR (MOTO-CAR) in imunotherapy
  • Macrophage CAR (MOTO-CAR) in imunotherapy
  • Macrophage CAR (MOTO-CAR) in imunotherapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0102] TK1 and HPRT are expressed only on the surface membrane of tumor cells and lead to the production of a series of monoclonal antibodies against human TK1 and HPRT. The specific binding capabilities of these specific monoclonal antibodies can be used in modified macrophage-specific chimeric antigen receptor-transduced macrophages for the treatment of cancer patients. Methods for modifying monocytes / macrophages to have anti-human TK1 receptors (MOTOCAR) may include production of human / humanized monoclonal antibodies specific for TK1 and HPRT ( figure 1 ). These TK1- and HPRT-specific monoclonal antibodies can be used to transduce macrophages ( Figure 3a , Figure 3b ) of the macrophage (MO) signaling domain ( figure 2 ) (for example from the cytoplasmic domain portion of a toll-like receptor (TO), FCγIII, IL-1 or INF-γ receptor) fusion ( Figure 7 ) to generate a chimeric antigen receptor (CAR). The premise is that monocytes / macrophages can be removed from the pati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Modified macrophage immune cells are provided for treatment of cancer and other diseases. In particular said macrophages express chimeric antigen receptors (CAR). The single chain variable fragment (scFv) may be directed against thymidine kinase 1 (TK1)or hypoxanthine guanine phosphoribosyltransferase (HPRT). The signaling domain may be derived from a Toll-like receptor (TLR).

Description

Background technique [0001] Cancer describes a group of diseases involving uncontrolled cell growth and death, genomic instability and mutation, protracted inflammation-promoting tumors, induction of angiogenesis, immune system evasion, dysregulation of metabolic pathways, immortal cell replication, and metastatic tissue invasion[ 1]. Cancer is the second leading cause of death after heart disease in the United States [2]. More than 1.6 million new cases of cancer are expected to be diagnosed each year, and more than 580,000 Americans are expected to die (approximately 1600 cancer deaths per day), accounting for nearly a quarter of all U.S. deaths [2,3]. [0002] The immune system plays an important role in the initiation and progression of cancer. Monocytes differentiated into macrophages display various responses according to different stimuli and exhibit different functions according to their surrounding microenvironment. Macrophages can be pro-inflammatory (M1) or anti-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/30A61K35/15A61K39/395A61P35/00C07K19/00C12N5/0786
CPCA61K35/15A61K39/0011A61K2039/505C07K14/70596C07K16/30C07K2317/31C07K2317/622C07K2317/626C07K2319/00C07K2319/02C07K2319/03C07K2319/33C07K2319/74A61P35/00A61K39/001162
Inventor 吉姆·奥尼尔斯科特·韦伯
Owner 迅雷生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap